Website
News25/Ratings12
News · 26 weeks42-82%
2025-10-262026-04-19
Mix3490d
- Insider12(35%)
- Other8(24%)
- SEC Filings7(21%)
- Earnings4(12%)
- Analyst3(9%)
Latest news
25 items- SECSEC Form DEFA14A filed by PROCEPT BioRobotics CorporationDEFA14A - PROCEPT BioRobotics Corp (0001588978) (Filer)
- SECSEC Form DEF 14A filed by PROCEPT BioRobotics CorporationDEF 14A - PROCEPT BioRobotics Corp (0001588978) (Filer)
- PRPROCEPT BioRobotics® to Report First Quarter 2026 Financial Results on April 29, 2026SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2026 after market close on Wednesday, April 29, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/rdtftqik/ Dial-in registration for sell-side research
- SECAmendment: SEC Form SCHEDULE 13G/A filed by PROCEPT BioRobotics CorporationSCHEDULE 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)
- PRSonder Capital Closes its Second Fund and Announces Participation from Major Healthcare SystemsSAN CARLOS, Calif., March 24, 2026 /PRNewswire/ -- Sonder Capital, a healthcare venture capital firm investing in companies revolutionizing the standard of care, today announced the closing of its second fund, Futures II. The fund includes participation from Mayo Clinic and Sutter Health, reflecting their collective interest in innovative technologies that have the potential to advance the future of patient care by enhancing access, improving quality and transforming the overall patient experience."Through our second fund we'll continue enabling the next wave of companies and he
- PREAU Guidelines Upgrade Aquablation® Therapy to Strong Surgical Recommendation for BPHSAN JOSE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (NASDAQ:PRCT) today highlighted the latest update to the European Association of Urology (EAU) Guidelines for male lower urinary tract symptoms (LUTS), which include an upgrade of Aquablation therapy to a strong recommendation as a surgical treatment option for men with benign prostatic hyperplasia (BPH). The EAU guidelines are widely regarded as one of the most rigorous and influential clinical guideline frameworks in urology globally. The updated guidelines now strongly recommend offering Aquablation therapy as an alternative to transurethral resection of the prostate (TURP) for men with moderate-to-severe urinary
- INSIDERSEC Form 4 filed by Nouri Alaleh4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDERSEC Form 4 filed by Nouri Alaleh4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDERSEC Form 4 filed by Waters Kevin4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- SECSEC Form 144 filed by PROCEPT BioRobotics Corporation144 - PROCEPT BioRobotics Corp (0001588978) (Subject)
- INSIDEREVP, CLO, CORP. SEC. Nouri Alaleh sold $83,197 worth of shares (3,243 units at $25.65), decreasing direct ownership by 3% to 111,021 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- PRPROCEPT BioRobotics® Announces International Launch of the HYDROS® Robotic System, Expanding Global Access to AI-Enabled Aquablation® TherapySAN JOSE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT), today announced the international expansion of the HYDROS Robotic System, the company's next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia (BPH). HYDROS is the first AI-enabled robotic platform designed specifically for the treatment of BPH with Aquablation therapy. Leveraging AI-interpreted, real-time ultrasound imaging and advanced image-guided treatment planning, the system enables surgeons to deliver personalized, anatomy-specific therapy with robotic precision and reproducibility. The platform is designed to support scalable adoption across care setti
- INSIDERDirector Desai Antal Rohit bought $10,482,943 worth of shares (426,262 units at $24.59) (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDERPresident, CEO Wood Larry L was granted 127,783 shares, increasing direct ownership by 69% to 313,378 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDEREVP, CLO, CORP. SEC. Nouri Alaleh sold $163,353 worth of shares (6,892 units at $23.70) and was granted 43,811 shares, increasing direct ownership by 48% to 114,264 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDEREVP, CFO Waters Kevin was granted 47,462 shares and sold $159,300 worth of shares (6,721 units at $23.70), increasing direct ownership by 37% to 152,264 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDERDirector Puckett Dan was granted 5,476 shares (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDERSEC Form 3 filed by new insider Puckett Dan3 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by PROCEPT BioRobotics CorporationSCHEDULE 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)
- ANALYSTRobert W. Baird initiated coverage on PROCEPT BioRobotics with a new price targetRobert W. Baird initiated coverage of PROCEPT BioRobotics with a rating of Neutral and set a new price target of $30.00
- SECSEC Form S-8 filed by PROCEPT BioRobotics CorporationS-8 - PROCEPT BioRobotics Corp (0001588978) (Filer)
- SECSEC Form 10-K filed by PROCEPT BioRobotics Corporation10-K - PROCEPT BioRobotics Corp (0001588978) (Filer)
- SECPROCEPT BioRobotics Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)
- PRPROCEPT BioRobotics® Hosts 2026 Investor Day to Detail Multi-year Financial Outlook and Strategic Plan for Long-Term GrowthCompany outlines path to leadership in BPH, including near-term focus on procedure growth through patient-centric solutions and increased organizational disciplineStrong revenue outlook, procedure growth, expanding margins, and path to profitabilityLonger-term growth drivers include market expansion and expanded application into prostate cancer NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today hosted its 2026 Investor Day event in New York to detail the Company's market opportunity, long-term strategy and growth goa
- ANALYSTPROCEPT BioRobotics downgraded by OppenheimerOppenheimer downgraded PROCEPT BioRobotics from Outperform to Perform